Report Subject - Generics/Biosimilars - Page 1

Learn More Biosimilars: EU Payer Perspectives

Leading European payer experts reveal the real impact of biosimilars over the last 12 months Keeping track of the dynamics and nuances of the biosimilars market is critical – not least because the $232 billion...

Compare
Learn More Charting the Global Biosimilar Pipeline

There are multiple biosimilars in development for a range of therapy areas from cancer and diabetes to ophthalmology and respiratory. High-value mAbs such as Roche's Avastin (bevacizumab), Abbvie's Humira (adalimumab)...

Compare
Learn More Commercialisation of Biosimilars: Team Tactics & Strategies Across the Product Lifecycle

Commercialisation of Biosimilars From bench to bedside, biosimilars continue to dominate boardroom discussions around the world. But after all the talking, what's the secret to success in this high stakes market?...

Compare
Learn More Commercialisation of Biologics: Benchmarking leading players

Commercialisation of Biologics: Benchmarking Leading Players It’s clear that the rapidly growing biologics sector holds a wealth of promise. The significant opportunities resulting from breaking new ground are...

Compare
Learn More The Future of Biosimilars in the USA: Mapping critical uncertainties and the impact of future events

The Future of Biosimilars in the USA Can pharma resolve the litigation frenzy hampering biosimilars' market entry in the US? Is too much focus on legal wrangling stifling healthy competition and innovation? And, as the...

Compare
Learn More Biosimilars Real World Evidence: Proving the point

Biosimilars Real World Evidence: Proving the point Biosimilar manufacturers face an uphill struggle to fully mobilise their product portfolio. Against a background of aggressive defence strategies by originator...

Compare
Learn More The Future of Biosimilars in Europe

Education is top priority as biosimilar mAbs enter the market With the recent approval of Celltrion’s Truxima, all eyes are on biosimilar oncology monoclonal antibodies (mAbs). Experts say they’re the next...

Compare
Learn More Biosimilars in Emerging Markets (2017)

Biosimilars: Make the most of high risk emerging market opportunities Emerging biosimilars markets are currently a $5billion opportunity with even more growth potential ahead. Lower drug costs and improved patient...

Compare
Learn More Biosimilars: US Payer Perspectives (2017)

Will biosimilar provide a ‘magic bullet’ to drug prices in the US? Payers speak out… Biosimilars continue to be big business in the US, but has progress has been too slow? Not so, argue payers...

Compare
Learn More The Future of Biobetters

Strategies for success in the biobetter market How can you successfully position biobetter products in the increasingly crowded branded biologic/biosimilar space? With the prospect of improving patient adherence,...

Compare
Learn More Biosimilars: European Payer Perspectives (2017)

What is the future for biosimilars in the EU? What issues do EU Payers think will impact adoption, pricing and reimbursement of biosimilars? In January 2016 Samsung Bioepis launched Benepali, a biosimilar version of...

Compare
Learn More Defending Against Biosimilars: Originator strategies

Battle of the biologics: How to survive The onward march of biologics has shaped a brave new world for drug manufacturers with conflicting rules and regulations and an eclectic mix of individual players to contend with...

Compare
Learn More Biosimilars Education: Addressing a significant unmet need

How to educate stakeholders about biosimilar benefits What information and data do physicians, payers and patients need about biosimilars? As the market expands and new therapeutic sectors come on stream, more...

Compare
Learn More Benchmarking Biologic Innovator Value-Added-Services

Delivering high-quality value-added services for biologics What are the “beyond-the-pill” services that biologic companies need to deliver to ensure improved patient compliance and outcomes? Patient, payer...

Compare
Learn More The Future of Biosimilars 2016

Development activity is surging as the focus shifts to commercialisation. How will the market evolve? The race to commercialise biosimilars is on. What will it take to create a thriving market? Will payers see real cost...

Compare
Learn More Biosimilars: US Payer Perspectives (2016)

Biosimilars have finally hit the US market. Now comes the hard part. The US Biosimilars market is open for business. What will it take to get customers in the door? Get our new report, Biosimilars: US Payer...

Compare

Browse by